Drugs / LV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07099794 Background | Aug 2025 → Feb 2029 expected | biliary tract cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07099794 ↗ |
| Route | Intravenous | “LV: 400 mg/m2 intravenously, d1 q2w” NCT07099794 ↗ |